Minerva Neurosciences, Inc. (NERV)

NCM – Цена в реальном времени. Валюта: USD

5.60

-0.03 (-0.53%)

При закрытии: May 12, 2026, 4:00 PM EDT

6.00

+0.40 (7.14%)

После закрытия: May 12, 2026, 7:44 PM EDT

05.05.2026

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported financial and business updates for the first quarter ended March 31, 2026.

02.04.2026

Minerva Announces Leadership Transition

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company.

31.03.2026

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia.

25.03.2026

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy.

12.03.2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.

11.03.2026

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027

04.03.2026

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

BURLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Citizens Life Sciences Conference being held March 10-11, 2026 in Miami, FL.

Видео

No Data

There is no data to display

Пресс-релизы

05.05.2026

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

02.04.2026

Minerva Announces Leadership Transition

31.03.2026

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

25.03.2026

Minerva Neurosciences, Inc. (NERV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Видео

No Data

Пресс-релизы

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Видео

No Data

Пресс-релизы

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Search stocks

Minerva Neurosciences, Inc. (NERV)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Minerva Neurosciences, Inc. (NERV)

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Видео

No Data

Пресс-релизы

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates

Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Видео

No Data

Пресс-релизы

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Announces Leadership Transition

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026